Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,048 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Clear all
Completed Phase 1 Interventional

Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines

NCT00698100
View directory record Official record
Conditions
Melanoma, Skin
Interventions
human tyrosinase, mouse tyrosinase
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 25, 2026, 12:15 AM EDT
Not listed Phase 2 Interventional

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer

NCT04024800
View directory record Official record
Conditions
Triple-negative Breast Cancer
Interventions
AE37 Peptide vaccine, Pembrolizumab
Biological
Lead sponsor
NuGenerex Immuno-Oncology
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Decatur, Illinois • Effingham, Illinois • Swansea, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 25, 2026, 12:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Protective Immunity Project 01

NCT00788021
View directory record Official record
Conditions
Kidney Transplantation, Immunity, Immunosuppression
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 25, 2026, 12:15 AM EDT
Completed Phase 2 Interventional Results available

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

NCT02243371
View directory record Official record
Conditions
Previously Treated Metastatic Adenocarcinoma of the Pancreas
Interventions
CRS-207, nivolumab, GVAX, CY
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
San Francisco, California • Stanford, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 25, 2026, 12:15 AM EDT
Terminated Not applicable Interventional

The Impact of Zinc Supplementation on Innate Immunity and Patient Safety in Sepsis

NCT02130388
View directory record Official record
Conditions
Sepsis
Interventions
Zinc
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 25, 2026, 12:15 AM EDT
Completed Phase 1 Interventional

Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

NCT00095160
View directory record Official record
Conditions
Neoplasms
Interventions
852A
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 25, 2026, 12:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

NCT03028974
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 49 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 25, 2026, 12:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

NCT00766597
View directory record Official record
Conditions
HIV Infections
Interventions
Vicriviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 25, 2026, 12:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

NCT05921903
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA Investigational Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Chicago, Illinois • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 25, 2026, 12:15 AM EDT
Not listed Not applicable Interventional

Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus

NCT00102934
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide-intensified HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2008 · Synced Oct 25, 2026, 12:15 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV

NCT07698600
View directory record Official record
Conditions
HIV -1 Infection
Interventions
BNT168, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 50 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 12:15 AM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

NCT00992836
View directory record Official record
Conditions
HIV Infections, H1N1 Influenza Virus
Interventions
Influenza A (H1N1) 2009 monovalent vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 25, 2026, 12:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Systems Biology Approach to Malaria Immunity

NCT03014258
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
NF54 P. falciparum malaria challenge
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 25, 2026, 12:15 AM EDT
Terminated No phase listed Observational

A Study of the Association Between Autism and Immune Changes in the Brain

NCT01322555
View directory record Official record
Conditions
Autism Spectrum Disorders, Brain Disease, Autism, Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 25, 2026, 12:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults

NCT03565315
View directory record Official record
Conditions
Healthy Adult Immune Response
Interventions
VRC-HIVMAB095-00-AB (10E8VLS), VRC-HIVMAB075-00-AB (VRC07-523LS)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 25, 2026, 12:15 AM EDT
Completed No phase listed Observational

Immune Responses to COVID-19 Infection or Vaccination

NCT05379478
View directory record Official record
Conditions
COVID-19
Interventions
Laboratory assessment of antibody profiles
Diagnostic Test
Lead sponsor
Aditxt, Inc.
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 25, 2026, 12:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Novel Experimental COVID-19 Therapies Affecting Host Response

NCT04924660
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions
TXA127, TRV027, Placebo, Fostamatinib
Drug
Lead sponsor
Sean Collins
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 25, 2026, 12:15 AM EDT
Recruiting Phase 2 Interventional

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

NCT04683679
View directory record Official record
Conditions
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Interventions
Pembrolizumab, Olaparib, Radiation
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 25, 2026, 12:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)

NCT01669603
View directory record Official record
Conditions
Common Cold
Interventions
Bifidobacterium lactis Bl-04, Placebo, Rhinovirus
Dietary Supplement · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 60 Years
Enrollment
789 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 25, 2026, 12:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults

NCT02408913
View directory record Official record
Conditions
Healthy Adult Immune Responses to Vaccine
Interventions
VRC-EBOMVA079-00-VP (MVA-EbolaZ), VRC-EBOADC069-00-VP (cAd3-EBO)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 66 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 25, 2026, 12:15 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States

NCT02153996
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 25, 2026, 12:15 AM EDT
Completed No phase listed Observational

HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study

NCT03744741
View directory record Official record
Conditions
Respiratory Tract Infections, Urinary Tract Infections, Skin and Soft Tissue Infections, Intraabdominal Infections, Sepsis
Interventions
HostDx Sepsis
Diagnostic Test
Lead sponsor
Inflammatix
Industry
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Atlanta, Georgia • Lexington, Kentucky • Springfield, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 25, 2026, 12:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Yellow Fever Immune Response at Single Cell Resolution

NCT03458780
View directory record Official record
Conditions
Healthy
Interventions
Yellow Fever Vaccine
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 59 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 25, 2026, 12:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines

NCT00197288
View directory record Official record
Conditions
Influenza
Interventions
Influenza
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,847 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
15
States / cities
Clearwater, Florida • Evansville, Indiana • Baltimore, Maryland + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 25, 2026, 12:15 AM EDT